Skip to content
OVistoaIntelligence index
AboutMethodologyPricingDocs
Sign inSign up
BREAKINGPerson found dead in car after it plows into health club in Portland, Oregon11 min ago
Top StoriesUnited StatesCanadaWorldPoliticsGeneralBusinessTechHealthAviationSportsArtificial IntelligencePublishers

Why the FDA rejected a ‘breakthrough’ melanoma drug

1 articles · 1 outlets · spread 0.00

Why the FDA rejected a ‘breakthrough’ melanoma drug
FDA10 hr ago

Why the FDA rejected a ‘breakthrough’ melanoma drug

Full coverage view across outlets, lean, source quality, and framing. Compare framing without algorithmic ranking.

1 articles1 outletsSpread 0.0012 claims
OVistoa

Article-level news analysis, transparent scoring, and API tools for readers, publishers, and teams that need source context.

DMCA and copyright review

Copyright owners can submit notices, counter-notices, and source material concerns through the dedicated review flow.

Open DMCA review

Product

  • Home
  • Feed
  • Search
  • Topics
  • Saved

Platform

  • About
  • Methodology
  • Home
  • Search
  • Saved
  • Me

From the Left

1 outlet
  • Scientific American·May 2

    Why the FDA rejected a ‘breakthrough’ melanoma drug

    For patients whose skin cancer doesn’t respond to traditional treatments, a new drug called RP1 has been a lifeline—at least for those who can get into a clinical trial. The drug has shown so much promise in such trials that, at the end of 2024, its development was placed on a fast track, with all signs pointing to a speedy approval by the Food and Drug Administration. But as of last month, the FDA has twice opted not to approve RP1, puzzling researchers and worrying drug developers.Approximately 110,000 new cases of melanoma are diagnosed each year in the U.S., and 2.2 percent of people will be diagnosed with it at some point during their life. In its early stages, melanoma skin cancer is highly treatable, with a greater than 99 percent survival rate. Once the disease spreads to other areas of the body, however, treatment becomes much more difficult, and the five-year survival rate dips to roughly 16 percent. Adding even one new option—such as RP1—for people whose melanoma has not responded to first-line treatments could make a big difference for patients’ prognoses.“There’s really no second-line treatments” for some patients, says Yana Najjar, director of the Clinical and Translational Research

From the Center

0 outlets

No coverage from this perspective yet.

From the Right

0 outlets

No coverage from this perspective yet.

Claim synthesis

Pro users see canonical claims across the cluster and which outlets reported each one.

Learn more

Outlets covering this story

Scientific American

First seen

May 2, 2026

Latest

May 2, 2026

Outlets

1

Diversity

100/100

  • Pricing
  • API docs
  • Publishers

    • Account

    • Sign in
    • Create account
    • Reader settings
    • API console

    Legal

    • Terms
    • Privacy
    • Security
    • DMCA

    © 2026 Vistoa. All rights reserved.

    Limited excerpts, attribution, analysis, and outbound publisher links remain core product boundaries.